TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01818284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 µg/kg in the morning daily for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis Procedure
Description: The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained.
Study: NCT04213378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting PTCA balloon
Description: Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® Please paclitaxel eluting balloon
Description: Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
Study: NCT00799591

Intervention type: OTHER
Intervention: Observational study so no intervention in the patient.
Description: Observational study so no intervention in the patient.
Study: NCT01549119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC-3S
Description: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC-3S
Description: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC-3S
Description: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC-3S
Description: Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison with experimental vaccine
Study: NCT00701181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: Necessity of laser treatment is assessed every three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 high
Description: 3 mg intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 middle
Description: 1 mg intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04523655 low
Description: 0.4 mg intravitreal injection
Study: NCT02924311

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
Study: NCT01656512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolendronic acid
Description: patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium & vitamin D
Description: patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
Study: NCT02072330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAK-536CCB
Description: TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
Study: NCT00415909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (IM)
Description: IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALL-104 cells
Description: TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
Study: NCT02930421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
Study: NCT05240404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
Study: NCT00895661

Intervention type: DRUG
Group type: OTHER
Intervention: rituximab
Description: Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
Study: NCT02211313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.
Description: Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.
Description: Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
Study: NCT03247959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game distraction and video distraction
Description: video game distraction and video distraction will be advocated during the extraction procedure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game distraction and video distraction
Description: video game distraction and video distraction will be advocated during the extraction procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game distraction and video distraction
Description: video game distraction and video distraction will be advocated during the extraction procedure
Study: NCT00599508

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord grape juice
Description: Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo juice
Description: several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
Study: NCT02072330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536CCB + Hydrochlorothiazide
Description: TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
Study: NCT00599508

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: blueberry juice
Description: wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whole fruit blueberry powder
Description: whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: berry placebo powder
Description: berry placebo powder administered daily for 16 weeks
Study: NCT01587365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476
Study: NCT05240404

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thermal ablation
Description: The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
Study: NCT01587365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476
Study: NCT03226431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
Study: NCT03626714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained Release Injectable Tacrolimus
Description: Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
Study: NCT03409172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: no counseling or nutritional therapy and no exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT
Description: no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
Study: NCT03529240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping
Description: Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
Study: NCT01436981

Intervention type: PROCEDURE
Intervention: CABG
Description: Preparation of artery mammaria interna
Study: NCT03586388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy protocol
Description: In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk.
Study: NCT01587365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-962476
Study: NCT02072330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536CCB + Hydrochlorothiazide
Description: TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
Study: NCT02709200

Intervention type: DRUG
Intervention: Dexmedetomidine
Study: NCT03953079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GB-102
Description: Intravitreal injection of GB-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GB-102
Description: Intravitreal injection of GB-102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection of aflibercept (2 mg dose)
Study: NCT03695822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg
Description: The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
Study: NCT00518297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Tablet, Oral, 400 mg, twice daily for 5 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsule, Oral, 300 mg, twice daily for 7 Days
Study: NCT01772303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HO/03/03 10-40 µg
Description: HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
Study: NCT01291056

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
Study: NCT00518297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Raltegravir
Description: Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
Study: NCT02134288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study: NCT02294734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for inhalation via DISKUS 'device'
Study: NCT01779635

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oXiris as first filter
Description: 2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots

Intervention type: DEVICE
Group type: OTHER
Intervention: M150 as first filter
Description: start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
Study: NCT04151277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-A
Description: Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabe and Abraxane
Description: Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
Study: NCT01160432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone, naloxone
Description: Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone, naloxone
Description: Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
Study: NCT04326088

Intervention type: OTHER
Intervention: Reconstruction group
Description: Patients with primary tumor which underwent free flap reconstruction group.

Intervention type: OTHER
Intervention: Recurrent group
Description: Patients with recurrent tumor which underwent free flap reconstruction group.
Study: NCT02968628

Intervention type: OTHER
Intervention: Video Electroencephalogram (EEG)
Description: Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.

Intervention type: OTHER
Intervention: Video Electroencephalogram (EEG)
Description: Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.

Intervention type: OTHER
Intervention: Point-of Care Blood Sugar Testing
Description: One-time heel-stick point-of-care blood sugar testing at time of EEG.

Intervention type: OTHER
Intervention: Point-of Care Blood Sugar Testing
Description: One-time heel-stick point-of-care blood sugar testing at time of EEG.

Intervention type: OTHER
Intervention: Medical Record Data Extraction
Description: Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.

Intervention type: OTHER
Intervention: Medical Record Data Extraction
Description: Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.

Intervention type: OTHER
Intervention: Maternal Questionnaire
Description: One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.

Intervention type: OTHER
Intervention: Maternal Questionnaire
Description: One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
Study: NCT00551291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1 gm twice daily orally until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg/day orally until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin Beta
Description: Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
Study: NCT01291056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
Study: NCT03989440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXER-204
Description: human NoGo Trap fusion protein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline formulation
Study: NCT03878914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
Study: NCT02647086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Cytochrome P450 substrate
Study: NCT03080337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Care
Description: Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
Study: NCT02225288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: transdermal E2022 tape formulation (8.1 cm x 8.1 cm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: transdermal E2022 tape formulation (8.1 cm x 8.1 cm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: transdermal E2022 tape formulation (8.1 cm x 8.1 cm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022
Description: transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
Study: NCT02647086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Cytochrome P450 substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Cytochrome P450 substrate